Evidence map›Paper›PMID 42811289›Full record

ArticleMolecular medicine (Cambridge, Mass.)2026

The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity.

Michelle Haß, Eleonora Mungo, Denis Benning, Andreas Weigert, Blerina Aliraj, Josefine Jakob, Björn Häupl, Thomas Oellerich, Nicole Ziegler, Aimo Kannt and 2 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michelle HaßGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany.
Eleonora MungoGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany.
Denis BenningGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany.
Andreas WeigertGoethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Theodor Stern Kai 7, Frankfurt am Main, 60590, Germany.
Blerina AlirajGoethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Theodor Stern Kai 7, Frankfurt am Main, 60590, Germany.
Josefine JakobGoethe University Frankfurt, University Hospital, Department of Medicine, Hematology and Oncology, Frankfurt Am Main, Germany.
Björn HäuplGoethe University Frankfurt, University Hospital, Department of Medicine, Hematology and Oncology, Frankfurt Am Main, Germany.
Thomas OellerichGoethe University Frankfurt, University Hospital, Department of Medicine, Hematology and Oncology, Frankfurt Am Main, Germany.
Nicole ZieglerFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Sandhöfer Allee 1, Frankfurt Am Main, 60528, Germany.
Aimo KanntGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany.
Gerd GeisslingerGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany.
Ellen NiederbergerGoethe-University Frankfurt, pharmazentrum frankfurt/ZAFES, Faculty of Medicine, Institute of Clinical Pharmacology, Theodor Stern Kai 7, Frankfurt Am Main, 60590, Germany. e.niederberger@em.uni-frankfurt.de.ORCID https://orcid.org/0000-0002-3909-5751

Funding

Deutsche Forschungsgemeinschaft GRK 2336Fraunhofer-Gesellschaft 445757098Hessisches Ministerium für Wissenschaft und Kunst 445757098
6 · The paper itself

Abstract

backgroundInhibitor of nuclear factor kappa-B kinase epsilon (IKKε) contributes to tumorigenesis and metastasis in various cancers. In melanoma, it is overexpressed and constitutively active. Inhibition of IKKε by either knockdown or pharmaceutical compounds reduce tumor progression by suppressing key molecular pathways within melanoma tumor cells. However, within the tumor microenvironment (TME), the role of this protein remains to be fully elucidated.

methodsMultiplex immunohistochemistry was performed on human primary melanomas to assess IKKε expression in tumor and immune cell compartments. In the mouse model, B16BL6 melanoma cells were injected subcutaneously into the flanks of wildtype and IKKε-deficient mice, and tumor growth was monitored over time. Flow-cytometric analyses characterized intratumoral immune cell populations in both genotypes, followed by in vivo CD8⁺ T-cell depletion to determine their contribution to tumor control. To elucidate molecular mechanisms underlying the differential tumor growth, we conducted targeted and untargeted proteomic analyses, which indicated regulation of angiogenic pathways which were further examined by assessing specific protein changes in tumor tissue and performing in vitro angiogenesis assays.

resultsThe reduced tumor growth observed in IKKε knock-out (KO) mice was concomitant with elevated levels of cytotoxic CD8⁺ and γδ-T-cells, and a diminished presence of neutrophils. Furthermore, our data revealed that isolated CD8⁺ T-cells from IKKε KO mice exhibited a higher activity in comparison to their wildtype counterparts. In addition, the depletion of CD8⁺ cells reversed the antitumor efficacy of IKKε depletion. Proteomic analysis of tumor lysates revealed a reduction of several chemokines in IKKε KO mice compared to wildtype controls, that might contribute to the reduced tumor growth and suggested that an inhibition of angiogenesis may support the antitumor activity in IKKε KO mice. This hypothesis could be confirmed by further protein analyses and angiogenesis assays.

conclusionsOur data imply that IKKε expression in melanoma is not only important in the tumor cells but also in the tumor microenvironment by regulation of the immune response and angiogenesis. Consequently, inhibition of IKKε may offer a novel therapeutic approach for melanoma, complementing existing therapies that target pathways within tumor cells and antitumor immune responses in the tumor microenvironment.

Indexed as

I-kappa B KinaseMelanomaNeovascularization, PathologicT-LymphocytesTumor MicroenvironmentAnimalsCell Line, TumorHumansMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutI-kappa B KinaseIKKεMelanomaT-cells, angiogenesisTumor growth

Identifiers

PMID42811289
PMCPMC13625450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.